溴隐亭联合神经内镜下经蝶窦切除术治疗垂体瘤的临床疗效及其对患者性激素水平的影响  

Clinical efficacy of bromocriptine combined with endoscopic transsphenoidal resection for the treatment of pituitary tumors and its impact on sex hormone levels

作　　者：火旭其 胥敏 王宏盛 高广忠 HUO Xu-qi;XU Min;WANG Hong-sheng;GAO Guang-zhong(Department of Neurosurgery,Yancheng Clinical College of Medicine,Nanjing Medical University,Yancheng 224001;Department of Neurosurgery,the Affiliated Taizhou People's Hospital of Nanjing Medical University,Taizhou 225300,Jiangsu,China)

机构地区：[1]南京医科大学,盐城临床医学院神经外科,江苏盐城224001 [2]南京医科大学,附属泰州人民医院神经外科,江苏泰州225300

出　　处：《川北医学院学报》2025年第2期241-244,共4页Journal of North Sichuan Medical College

基　　金：江苏医药职业学院临床学院专项科研发展基金(20219103)。

摘　　要：目的:探讨溴隐亭联合神经内镜下经蝶窦切除术治疗垂体瘤的临床疗效及其对患者性激素水平的影响。方法:选取98例拟行神经内镜下经蝶窦切除术治疗的垂体瘤患者为研究对象,按术前是否使用溴隐亭分为溴隐亭组和对照组,每组各49例。对照组术前不使用溴隐亭;溴隐亭组术前3 d服用溴隐亭,术后随访3个月。比较两组患者临床疗效、应激指标[肾上腺素(E)、去甲肾上腺素(NE)、皮质醇(R)及血管紧张素Ⅱ(ATⅡ)水平]、性激素[生长激素(GH)、催乳素(PRL)及促甲状腺激素(TSH)]水平及生活质量[健康检查简表(SF-36)评分]。结果:溴隐亭组临床总有效率高于对照组(95.92%vs.83.67%,P<0.05)。术后1个月,两组患者E、NE、R、ATⅡ水平均升高(P<0.05),但溴隐亭组低于对照组(P<0.05);GH、PRL、TSH水平降低(P<0.05),且溴隐亭组低于对照组(P<0.05)。术后1个月及3个月,两组患者SF-36评分均升高(P<0.05),且溴隐亭组均高于对照组(P<0.05)。结论:溴隐亭联合神经内镜下经蝶窦切除术治疗垂体瘤的临床疗效确切,可有效降低患者的性激素水平,稳定患者术后的应激指标,提高患者生活质量。Objective:To investigate the clinical efficacy of bromocriptine combined with endoscopic transsphenoidal resection for the treatment of pituitary tumors and its impact on patients'sex hormone levels.Methods:A total of 98 patients with pituitary tumors who were scheduled to undergo endoscopic transsphenoidal resection of the pituitary gland were selected for the study.They were divided into a bromocriptine group and a control group according to whether bromocriptine was used before surgery,49 cases in each group.Both groups underwent endoscopic transsphenoidal resection of the pituitary gland,and the bromocriptine group was treated with bromocriptine three days before surgery,both groups was followed up for 3 months after surgery.The clinical efficacy,stress indicators[adrenaline(E),norepinephrine(NE),cortisol(R),and angiotensin II(ATII)levels],sex hormone levels[growth hormone(GH),prolactin(PRL),and thyroid stimulating hormone(TSH)],and quality of life(SF-36 score)before and after surgery were compared between the two groups.Results:The total effective rate of the bromocriptine group was higher than that of the control group's(95.92%vs.83.67%,P<0.05).Compared with preoperative levels,the E,NE,R,and ATⅡof both groups of patients increased 1 month after surgery(P<0.05),the bromocriptine group was lower than the control group(P<0.05).Compared with preoperative levels,both groups of patients showed a decrease in GH,PRL,and TSH levels(P<0.05),and the bromocriptine group was lower than the control group(P<0.05).At 1 and 3 months after surgery,the SF-36 scores of both groups of patients improved(P<0.05),and bromocriptine group was higher than the control group(P<0.05).Conclusion:The clinical efficacy of bromocriptine combined with endoscopic transsphenoidal resection for pituitary tumors is definite,which can effectively reduce the patient's sex hormone levels,stabilize the patient's postoperative stress indicators,and improve the patient's quality of life.

关 键 词：溴隐亭 神经内镜 经蝶窦切除术 垂体瘤 性激素 

分 类 号：R736.4[医药卫生—肿瘤]